Key result
BM-531 prevents platelet aggregation and TXB2 production in vitro by inhibiting thromboxane receptors and synthase.
Population
Human washed platelets, human citrated platelet-rich plasma, whole blood from healthy donors, and rat fundus
Comparison
BM-531 (N-tert-butyl-N'-[sulfonyl]urea) vs Sulotroban and SQ-29548 (for receptor affinity)
Design
Preclinical
Authors
Loading...
BM-531 merits clinical evaluation as a novel antiplatelet; leaves open translation to human efficacy and safety.
BM-531 is a novel, potent thromboxane receptor antagonist and synthase inhibitor with promising antiplatelet properties in preclinical models.
Dogné et al. (2001) studied this question. BM-531 vs. sulotroban, SQ-29548 was evaluated on Platelet aggregation and TXB2 production. BM-531 is a potent thromboxane receptor antagonist and synthase inhibitor that prevents platelet aggregation and TXB2 production in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: